Volcker Rule Relief Act of 2018

Regulation of online lenders, including potential national charter, application of banking regulations, and H.R.5659, the "Volcker Rule Relief Act of 2018." Securitization of student loans.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Regulation of online lenders, including potential national charter, application of banking regulations, and H.R.5659, the "Volcker Rule Relief Act of 2018." Securitization of student loans.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Discussion draft legislation on Volcker Rule clarification and Dodd-Frank repeal; HR 4790, the Volcker Rule Regulatory Harmonization Act.; S. 2155, the Economic Growth, Regulatory Relief and Consumer Protection Act,; HR 5659 Volcker Rule Relief Act of 2018.

Client expense: $230,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

Discussion draft legislation on Volcker Rule clarification and Dodd-Frank repeal; HR 4790, the Volcker Rule Regulatory Harmonization Act.; S. 2155, the Economic Growth, Regulatory Relief and Consumer Protection Act,; HR 5659 Volcker Rule Relief Act of 2018.

Client expense: $220,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE

General issues related to consumer lending; S.2155, Economic Growth, Regulatory Relief, and Consumer Protection Act (P.L.115-174); H.R.4790, Volcker Rule Regulatory Harmonization Act; H.R.5659, Volcker Rule Relief Act of 2018.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of

General issues related to consumer lending; S.2155, Economic Growth, Regulatory Relief, and Consumer Protection Act (P.L.115-174); H.R.4790, Volcker Rule Regulatory Harmonization Act; H.R.5659, Volcker Rule Relief Act of 2018.

Client expense: $320,000 · Firm income: Not reported

Government targets: Executive Office of the President (EOP), Federal Deposit Insurance Corporation (FDIC), HOUSE OF REPRESENTATIVES, SENATE

Supplemental capital issues, regulatory issues for credit unions and tax exemption status: HR 10, HR 389, HR 1018, HR 1031, HR 1116, HR 1153, HR 1244, HR 1264, HR 1401, HR 1422, HR 1423, HR 1426, HR 1457, HR 1699, HR 1801, HR 1958, HR 1964, HR 2133, HR 2170, HR 2215, HR 2226, HR 2246, HR 2359, HR 2403, HR 2553, HR 2570, HR 2706, HR 2793, HR 2868, HR 2874, HR 2875, HR 2877, HR 2890, HR 2954, HR 3072, HR 3110, HR 3221, HR 3312, HR 3354, HR 3746, HR 3758, HR 3766, HR 3857, HR 3866, HR 3971, HR 3978, HR 4081, HR 4296, HR 4439, HR 4464, HR 4499, HR 4545, HR 4648, HR 4651, HR 4743, HR 4746, HR 4764, HR 4771, HR 4790, HR 4861, HR 4905, HR 5076, HR 5166, HR 5266, HR 5288, HR 5470, HR 5474, HR 5484, HR 5502, HR 5659, HR 5673, HR 5793, HR 5877, HR 5993, HR 6068, HR 6102, HR 6147, HR 6158, HR 6163, HR 6192, HR 6411, HR 6531, HR 6625, HR 6743, HR 6746, HR 6789, HR 6858, HR 6861, HR 6892, HR 6972; HJ Res 62, HJ Res 73, HJ Res 122, HJ Res 132; S 21, S 105, S 223, SJ Res 19, S 365, S 366, S 370, S 387, S 488, S 563, S 567, S 836, S 838, S 1002, S 1152, S 1264, S 1284, S 1313, S 1315, S 1368, S 1389, S 1499, S 1571, S 1579, S 1642, S 1753, S 1810, S 1962, S 1982, S 2155, S 2171, S 2237, S 2289, S 2362, S 2375, S 2417, S 2490, S 2701, S 2702, S 2862, S 3032, S 3040, S 3070, S 3128, S 3139, S 3334, S 3343, S 3443; SJ Res 47 SJ Res 56, SJ Res 57; data security and cybersecurity: patent reform; FHLB membership rules; CFPB and FSOC reform; and GSE reform.

Client expense: Not reported · Firm income: $50,000

S. 2155 - Economic Growth, Regulatory Relief, and Consumer Protection Act - section 203, Community Bank Relief. H.R. 4790 - Volcker Rule Regulatory Harmonization Act - Entire bill. H.R. 5659 - Volcker Rule Relief Act of 2018 - Entire bill.

Client expense: Not reported · Firm income: $30,000

Government targets: Federal Reserve System, HOUSE OF REPRESENTATIVES

Regulation of online lenders, including potential national charter, application of banking regulations, S.2155, the "Economic Growth, Regulatory Relief, and Consumer Protection Act," and H.R.5659, the "Volcker Rule Relief Act of 2018." Securitization of student loans.

Client expense: Not reported · Firm income: $60,000

Government targets: Federal Deposit Insurance Corporation (FDIC), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE

Regulation of online lenders, including potential national charter, application of banking regulations, S.2155, the "Economic Growth, Regulatory Relief, and Consumer Protection Act," and H.R.5659, the "Volcker Rule Relief Act of 2018." Securitization of student loans.

Client expense: Not reported · Firm income: $60,000

Government targets: Federal Deposit Insurance Corporation (FDIC), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE

Discussion draft legislation on Volcker Rule clarification and Dodd-Frank repeal; HR 4790, the Volcker Rule Regulatory Harmonization Act.; S. 2155, the Economic Growth, Regulatory Relief and Consumer Protection Act,; HR 5659 Volcker Rule Relief Act of 2018.

Client expense: $230,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

General issues related to consumer lending; S.2155, Economic Growth, Regulatory Relief, and Consumer Protection Act (P.L.115-174); H.R.4790, Volcker Rule Regulatory Harmonization Act; H.R.5659, Volcker Rule Relief Act of 2018.

Client expense: Not reported · Firm income: $60,000

Government targets: Federal Reserve System, HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of

S. 2155 - Economic Growth, Regulatory Relief, and Consumer Protection Act - section 203, Community Bank Relief. H.R. 4790 - Volcker Rule Regulatory Harmonization Act - Entire bill. H.R. 5659 - Volcker Rule Relief Act of 2018 - Entire bill.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Supplemental capital issues, regulatory issues for credit unions and tax exemption status: HR 10, HR 389, HR 1018, HR 1031, HR 1116, HR 1153, HR 1244, HR 1264, HR 1401, HR 1422, HR 1423, HR 1426, HR 1457, HR 1699, HR 1801, HR 1958, HR 1964, HR 2133, HR 2170, HR 2215, HR 2226, HR 2246, HR 2359, HR 2403, HR 2553, HR 2570, HR 2706, HR 2793, HR 2868, HR 2874, HR 2875, HR 2877, HR 2890, HR 2954, HR 3072, HR 3110, HR 3221, HR 3312, HR 3354, HR 3746, HR 3758, HR 3766, HR 3857, HR 3866, HR 3971, HR 3978, HR 4081, HR 4296, HR 4439, HR 4464, HR 4499, HR 4545, HR 4648, HR 4651, HR 4743, HR 4746, HR 4764, HR 4771, HR 4790, HR 4861, HR 4905, HR 5076, HR 5166, HR 5266, HR 5288, HR 5470, HR 5474, HR 5484, HR 5502, HR 5659, HR 5673, HR 5793, HR 5877, HR 5993, HR 6068, HR 6102, HR 6158, HR 6163, HR 6192; HJ Res 62, HJ Res 73, HJ Res 122, HJ Res 132; S 21, S 105, S 223, SJ Res 19, S 365, S 366, S 370, S 387, S 563, S 567, S 836, S 838, S 1002, S 1152, S 1264, S 1284, S 1313, S 1315, S 1368, S 1389, S 1499, S 1571, S 1579, S 1642, S 1753, S 1810, S 1962, S 1982, S 2155, S 2171, S 2237, S 2289, S 2362, S 2375, S 2417, S 2490, S 2701, S 2702, S 2862, S 3032, S 3040, S 3070, S 3128, S 3139; SJ Res 47 SJ Res 56, SJ Res 57; data security and cybersecurity: patent reform; FHLB membership rules; CFPB and FSOC reform; and GSE reform.

Client expense: Not reported · Firm income: $50,000

General issues related to consumer lending; S.2155, Economic Growth, Regulatory Relief, and Consumer Protection Act (P.L.115-174); H.R.4790, Volcker Rule Regulatory Harmonization Act; H.R.5659, Volcker Rule Relief Act of 2018.

Client expense: $400,000 · Firm income: Not reported

Government targets: Federal Reserve System, HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of

Regulation of online lenders, including potential national charter, application of banking regulations, S.2155, the "Economic Growth, Regulatory Relief, and Consumer Protection Act," and H.R.5659, the "Volcker Rule Relief Act of 2018." Securitization of student loans.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Regulation of online lenders, including potential national charter, application of banking regulations, S.2155, the "Economic Growth, Regulatory Relief, and Consumer Protection Act," and H.R.5659, the "Volcker Rule Relief Act of 2018." Securitization of student loans.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

The Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); The Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on Federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); the Medicare Access and CHIP Reauthorization Act of 2015 (H.R.1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The End Stage Renal Disease Choice Act (H.R. 5659); CMS 3337-ATII Medicare Program: Conditions for Coverage for End Stage Renal Disease - Third Party Payment; 21st Century Cures Act (H.R.6).

Client expense: Not reported · Firm income: $60,000

The Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); The Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on Federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); the Medicare Access and CHIP Reauthorization Act of 2015 (H.R.1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The End Stage Renal Disease Choice Act (H.R. 5659); CMS 3337-ATII Medicare Program: Conditions for Coverage for End Stage Renal Disease - Third Party Payment; 21st Century Cures Act (H.R.6).

Client expense: Not reported · Firm income: $60,000

The Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); The Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on Federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); the Medicare Access and CHIP Reauthorization Act of 2015 (H.R.1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The End Stage Renal Disease Choice Act (H.R. 5659); CMS 3337-ATII Medicare Program: Conditions for Coverage for End Stage Renal Disease - Third Party Payment; 21st Century Cures Act (H.R.6).

Client expense: Not reported · Firm income: $30,000

Implementation of the Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); The Medicare Access and CHIP Reauthorization Act of 2015 (H.R. 1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The ERSD Choice Act (H.R. 5659); Issues related to ERSD Program; S. 598 and H.R. 1130, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Medicare Advantage; Senate Finance Committee Chronic Care Working Group; Integrated care legislation; Access to coverage in Health Insurance Marketplaces for ESRD; Implementation of Pub. L. 114-27, the Trade Preferences Extension Act of 2015; OCR anti-discrimination proposed and final rules; ERSD quality programs; ERSD payment rules; ESRD prospective payment system CY 2017; Quality Incentive Program PY 2020 Final Rule

Client expense: $140,000 · Firm income: Not reported

Implementation of the Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); The Medicare Access and CHIP Reauthorization Act of 2015 (H.R. 1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The ERSD Choice Act (H.R. 5659); Issues related to ERSD Program; S. 598 and H.R. 1130, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Medicare Advantage; Senate Finance Committee Chronic Care Working Group; Integrated care legislation; Access to coverage in Health Insurance Marketplaces for ESRD; Implementation of Pub. L. 114-27, the Trade Preferences Extension Act of 2015; OCR anti-discrimination proposed and final rules; ERSD quality programs; ERSD payment rules; ESRD prospective payment system CY 2017; Quality Incentive Program PY 2020 Final Rule

Client expense: $140,000 · Firm income: Not reported

The Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); The Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on Federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); the Medicare Access and CHIP Reauthorization Act of 2015 (H.R.1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The End Stage Renal Disease Choice Act (H.R. 5659); CMS 3337-ATII Medicare Program: Conditions for Coverage for End Stage Renal Disease - Third Party Payment; 21st Century Cures Act (H.R.6).

Client expense: Not reported · Firm income: $100,000

The Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); The Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on Federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); the Medicare Access and CHIP Reauthorization Act of 2015 (H.R.1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The End Stage Renal Disease Choice Act (H.R. 5659); CMS 3337-ATII Medicare Program: Conditions for Coverage for End Stage Renal Disease - Third Party Payment; 21st Century Cures Act (H.R.6).

Client expense: Not reported · Firm income: $100,000

The Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); The Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on Federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); the Medicare Access and CHIP Reauthorization Act of 2015 (H.R.1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The End Stage Renal Disease Choice Act (H.R. 5659); CMS 3337-ATII Medicare Program: Conditions for Coverage for End Stage Renal Disease - Third Party Payment; 21st Century Cures Act (H.R.6).

Client expense: Not reported · Firm income: $40,000

Implementation of the Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); The Medicare Access and CHIP Reauthorization Act of 2015 (H.R. 1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The ERSD Choice Act (H.R. 5659); Issues related to ERSD Program; S. 598 and H.R. 1130, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Medicare Advantage; Senate Finance Committee Chronic Care Working Group; Integrated care legislation; Access to coverage in Health Insurance Marketplaces for ESRD; Implementation of Pub. L. 114-27, the Trade Preferences Extension Act of 2015; OCR anti-discrimination proposed and final rules; ERSD quality programs; ERSD payment rules.

Client expense: $230,000 · Firm income: Not reported

Implementation of the Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); The Medicare Access and CHIP Reauthorization Act of 2015 (H.R. 1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The ERSD Choice Act (H.R. 5659); Issues related to ERSD Program; S. 598 and H.R. 1130, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Medicare Advantage; Senate Finance Committee Chronic Care Working Group; Integrated care legislation; Access to coverage in Health Insurance Marketplaces for ESRD; Implementation of Pub. L. 114-27, the Trade Preferences Extension Act of 2015; OCR anti-discrimination proposed and final rules; ERSD quality programs; ERSD payment rules.

Client expense: $230,000 · Firm income: Not reported